Efferon CT Blood Filtering for Cardiogenic Shock After Heart Attack
Tests a blood-filtering device in adults with heart attack and cardiogenic shock.
Plain-language title generated from the registry record
Registry title: Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Key facts
- Where
- Tomsk, RussiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06955936, who can take part
Where in Russia
- Tomsk NRMC Cardiology Research InstituteTomsk, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Efferon JSC
- Trial code
- NCT06955936
- Record updated
- 26 August 2026
- Original description
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.Read full original descriptionShow less
An Open Randomized Study on the Efficacy and Safety of Hemoadsorption With Efferon CT in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.
Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop.
The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.
Inclusion: Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction; Stages B - C of cardiogenic shock according to SCAI; Patient condition allows treatment with Efferon® CT device for at least 4 hours; SOFA score 12 or less.
Exclusion: Broken-heart syndrome (takotsubo cardiomyopathy); Acute myocardial infarction within the last 4 weeks; Cardiac trauma; Chronic kidney disease, stage 5 D (requiring continuous hemodialysis); Patients on immunosuppressive therapy for cancer and autoimmune diseases; Any other clinical condition of the patient that in the opinion of the investigator precludes inclusion in this study; Postcardiotomy cardiogenic shock; Myocarditis; Charlson comorbidity index greater than 9 points; Acute pulmonary embolism; Acute cerebral circulatory collapse; Transfusion reaction; Pregnancy.